thebench.bio

Regulatory Daily Summary

Regulatory Daily Summary: What Happened on October 6, 2026

UK adopts 44 health-AI recommendations and opens new testing phase

The DOJ narrowed corporate fraud priorities, putting health care, drug diversion and FDA violations in focus.

  • Updated
  • Read from 3 articles, 3 publications
  • F

Today in brief

The UK accepted all 44 recommendations on health-care AI regulation and opened a new round of testing for oversight of AI medical devices after they reach the market.1 A DOJ directive named four areas for priority corporate investigations, including health care fraud, drug diversion and violations of FDA law.2

UK accepts all 44 health-AI recommendations

The UK government accepted all 44 recommendations from its National Commission into the Regulation of AI in Healthcare and outlined plans to deliver them across the country.1 The Medicines and Healthcare products Regulatory Agency opened applications for the third phase of its AI Airlock program, which will test post-market monitoring and lifecycle oversight for AI-enabled medical devices.1

The agency said it plans to issue draft guidance on managing changes to these devices by December 2026 and consult in 2027 on how to qualify and classify them.1 The government committed to exploring staged authorization that could allow some AI tools into National Health Service use earlier under supervision while further real-world evidence is gathered.1

A full implementation roadmap, with timelines and responsibilities, is due by spring 2027, and the AI Airlock program has secured three more years of government funding.1 The first participants in the third phase are expected to be selected in November 2026.1

DOJ names health care and FDA conduct among corporate fraud priorities

On October 1, Assistant Attorney General Colin M. McDonald issued a directive identifying four areas for priority corporate investigations, including health care fraud, drug diversion and violations of the Federal Food, Drug, and Cosmetic Act.2

The directive narrows the department's corporate enforcement focus after its April 2026 launch of a department-wide Corporate Enforcement and Voluntary Self-Disclosure Policy.2 Legal commentators Andrew J. Hull and Anne K. Walsh said the directive tells prosecutors how to apply that policy, rather than changing it.2

Also worth knowing

  • Optogenetics received Nobel Prize recognition as its first therapy neared an FDA decision.3

Also published